financetom
Business
financetom
/
Business
/
Canopy Growth Says to Strengthen Balance Sheet with Early Prepayments Set to Reduce Term Loan by US$50 Million
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canopy Growth Says to Strengthen Balance Sheet with Early Prepayments Set to Reduce Term Loan by US$50 Million
Jul 29, 2025 1:52 PM

04:44 PM EDT, 07/29/2025 (MT Newswires) -- Canopy Growth ( CGC ) , a global cannabis company, on Tuesday after trade said it entered into an agreement with certain of its lenders to make three prepayments that are expected to reduce the company's Senior Secured Term Loan by US$50 Million by March 31, 2026.

A statement noted the agreement was entered into in order to facilitate the Acreage financing.

Under the terms of the agreement, Canopy Growth ( CGC ) will make the following prepayments under the Term Loan: US$25 million at par on or about July 31, 2025; and US$10 million at par on or prior to December 31, 2025; and US$15 million at par on or prior to March 31, 2026. When completed, the prepayments are expected to reduce the Canopy's interest expense under the Term Loan by approximately US$6.5 million on an annualized basis, the statement said.

"These prepayments reflect our continued focus on strengthening our balance sheet and lowering cash interest expense," said Luc Mongeau, Chief Executive Officer. "Reducing debt is essential to creating the financial flexibility Canopy Growth's ( CGC ) needs to drive sustainable growth now and in the future."

In connection with the agreement, Canopy USA, LLC obtained consent from the company in order for Canopy USA to secure an additional US$22 million in funding for Acreage Holdings and its subsidiaries. The Acreage Financing Consent required the consent of the Lenders.

Canopy shares closed down $0.12 to $1.40 on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved